A new development in pancreatic cancer treatment
This article has been medically reviewed by Dr Robert Lim.
A new targeted treatment has been approved in the United States for certain patients with advanced pancreatic cancer, adding another option to a disease that has historically been difficult to treat.
In August 2026, the U.S. Food and Drug Administration (FDA) approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have previously received systemic treatment, or who are not suitable for multiagent systemic therapy.
In the clinical trial supporting its FDA approval, 500 adults with metastatic pancreatic adenocarcinoma received either daraxonrasib or standard chemotherapy as second-line treatment after initial first-line chemotherapy. Results showed that daraxonrasib doubled median survival as compared to chemotherapy (13.2 months compared to 6.7 months).
How does the new treatment work?
Daraxonrasib is a type of targeted therapy known as a RAS inhibitor.
RAS is a group of proteins that helps control how cells grow. One way to think about RAS is as a growth switch inside the cell. In many pancreatic cancers, this switch becomes overly active, allowing cancer cells to continue growing. Daraxonrasib is designed to interfere with RAS and disrupt these growth signals.
This differs from chemotherapy, which acts more broadly on rapidly dividing cells. Targeted therapies instead focus on particular features or processes that cancer cells depend on.
This encouraging development offers an additional treatment option for patients with pancreatic cancer who meet the treatment criteria.
Where does it fit into pancreatic cancer treatment?
Pancreatic cancer treatment has evolved considerably, and there is no single approach that is right for everyone.
Surgery may be considered when the cancer can be completely removed. Chemotherapy remains an important treatment at different stages of the disease. Radiotherapy may also have a role for some patients.
Alongside these established treatments, targeted therapies are giving us another way to approach pancreatic cancer in selected patients.
What is particularly interesting is the shift towards understanding what is driving an individual patient's cancer. As we learn more about the biological changes within cancer cells, we may be able to identify treatments that target some of these changes more specifically.
What does this mean for patients?
For patients, a new treatment offers another possibility, but its suitability depends on each person's individual circumstances.
Treatment decisions consider the stage of the cancer, previous treatments, overall health and the goals of treatment. Supportive and palliative care can also play an important role in pancreatic cancer management.
The approval of daraxonrasib is an encouraging development, adding an option for patients who meet the treatment criteria and reflecting continued progress in pancreatic cancer treatment.
A growing understanding of each person's cancer offers hope for more personalised treatment, with care tailored to individual needs.
If you or a loved one has been diagnosed with pancreatic cancer, speak with your oncologist about the treatment options that may be appropriate for your individual circumstances.
Writer’s note: Daraxonrasib is not currently listed in the Cancer Drug List (CDL) and is available through the special access route.
